Axsome Therapeutics Files 8-K

TL;DR

AXSM filed an 8-K, likely an update for investors.

AI Summary

Axsome Therapeutics, Inc. filed an 8-K on June 5, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.

Why It Matters

This filing indicates Axsome Therapeutics is providing updates to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural update and does not appear to contain immediately concerning information.

Key Players & Entities

• Axsome Therapeutics, Inc. (company) — Registrant
• June 05, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-37635 (commission_file_number) — SEC File Number
• 45-4241907 (irs_number) — IRS Employer Identification No.
• One World Trade Center, 22nd Floor (address) — Principal Executive Offices
• New York (location) — City of Principal Executive Offices
• New York (state) — State of Principal Executive Offices
• 10007 (zip_code) — Zip Code of Principal Executive Offices
• (212) 332-3241 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market

Filing Documents

• axsm-20240605.htm (8-K) — 40KB
• axsm-ex99_1.htm (EX-99.1) — 16KB
• img36028404_0.jpg (GRAPHIC) — 22KB
• 0000950170-24-069077.txt ( ) — 198KB
• axsm-20240605.xsd (EX-101.SCH) — 23KB
• axsm-20240605_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On June 5, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that it has entered into a settlement agreement with Unichem Laboratories Ltd. ("Unichem") resolving patent litigation related to the Company's product, Sunosi (solriamfetol) ("SUNOSI"). The litigation, which is pending in the U.S. District Court for the District of New Jersey, resulted from submission by Unichem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of SUNOSI in the United States. The settlement agreement permits Unichem to begin selling its generic version of SUNOSI on June 30, 2042, or earlier under certain circumstances. The June 30, 2042 date is also subject to potential extension for pediatric exclusivity. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The description of the settlement agreement contained herein does not purport to be complete. Similar patent litigation brought by Axsome against other parties remains pending in the U.S. District Court for the District of New Jersey. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated June 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: June 5, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR